Orion Biotechnology Publishes Whitepaper Highlighting the Importance and Challenges in Unlocking “Undruggable” GPCRs
February 02, 2023 10:07 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G...
Orion Biotechnology Shares In Vivo Efficacy Data on its Latest Best-in-Class Drug Candidate
December 01, 2022 11:08 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G...
Orion Biotechnology to Attend the LSX Investival Showcase and Jefferies Healthcare Conference
November 10, 2022 09:03 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Ontario, Canada, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously...
Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins
October 14, 2020 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...